Results 11 to 20 of about 519,893 (158)

mRNA-1273 is placenta-permeable and immunogenic in the fetus [PDF]

Molecular Therapy: Nucleic Acids
COVID-19 mRNA vaccines are generally recognized as safe for gestational administration. However, their transplacental pharmacokinetics remain obscure. In this study, mRNA-1273 intramuscularly given to pregnant mice rapidly circulated in maternal blood ...
Jeng-Chang Chen, Mei-Hua Hsu, Rei-Lin Kuo, Li-Ting Wang, Ming-Ling Kuo, Li-Yun Tseng, Hsueh-Ling Chang, Cheng-Hsun Chiu   +7 more
doaj   +3 more sources

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents [PDF]

Human Vaccines & Immunotherapeutics
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12–17 years), with and without pre-booster SARS-CoV-2 infection.
Amparo L. Figueroa, Kashif Ali, Gary Berman, Wenqin Xu, Weiping Deng, Bethany Girard, Anne Yeakey, Karen Slobod, Jacqueline Miller, Rituparna Das, Frances Priddy   +10 more
doaj   +3 more sources

Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters [PDF]

Frontiers in Immunology
BackgroundCharacterizing the antibody epitope profiles of messenger RNA (mRNA)-based vaccines against SARS-CoV-2 can aid in elucidating the mechanisms underlying the antibody-mediated immune responses elicited by these vaccines.MethodsThis study ...
Bethany Girard, Elisabeth Baum-Jones, Rebecca L. Best, Thomas W. Campbell, Jack Coupart, Kyla Dangerfield, Abhilash Dhal, Michael Jhatro, Brian Martinez, Jack Reifert, John Shon, Minlu Zhang, Rebecca Waitz, Spyros Chalkias, Darin K. Edwards, Maha Maglinao, Robert Paris, Rolando Pajon   +17 more
doaj   +3 more sources

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases [PDF]

Nature Communications
Primary vaccination with mRNA-1273 (100-µg) was safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A of the phase 3 Coronavirus Efficacy (COVE; NCT04470427) trial in adults (≥18 years) across ...
Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Dean Follmann, Gregory Hachigian, Cynthia Strout, J. Scott Overcash, Susanne Doblecki-Lewis, Jennifer A. Whitaker, Evan J. Anderson, Kathleen Neuzil, Lawrence Corey, Frances Priddy, Joanne E. Tomassini, Mollie Brown, Bethany Girard, Dina Stolman, Veronica Urdaneta, Xiaowei Wang, Weiping Deng, Honghong Zhou, Avika Dixit, Rituparna Das, Jacqueline M. Miller, the COVE Trial Consortium   +24 more
doaj   +3 more sources

Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review

Expert Review of Vaccines, 2023
Introduction Current safety data from Phase 3 clinical trials have concluded that apart from transient local and systemic reactions, no safety concerns were identified for the Moderna COVID-19 vaccine (mRNA-1273).
Angel Shabu, Prasad S. Nishtala
doaj   +2 more sources

Signatures of Trained Immunity Following mRNA Vaccination: Differences Between mRNA-1273 and BNT162b2 [PDF]

J Clin Immunol
Trained immunity, a de-facto innate immune memory, has been extensively studied in response to live-attenuated vaccines, but its presence following the new COVID-19 vaccines has not yet been fully elucidated.
Østergaard, Lars Jørgen, 8stergaard, Lars J\uf8rgen, Wejse, Christian Morberg, Whitehead, Bradley Joseph, Tolstrup, Martin, Kunc, Martin, Nejsum, Peter, Benn, Christine Stabell; id_orcid, Benn, Christine Stabell   +8 more
core   +2 more sources

Safety and Immunogenicity of an mRNA-1273 Booster in Children [PDF]

Clin Infect Dis
Background: A 2-dose mRNA-1273 primary series in children aged 6 months-5 years (25 µg) and 6-11 years (50 µg) had an acceptable safety profile and was immunogenic in the phase 2/3 KidCOVE study.
Nachman, Sharon, Rathore, Mobeen, Miller, Jacqueline, de Leon, Liberation, Yeakey, Anne, Girard, Bethany, Rodriguez, Carina A, Rostad, Christina A, Pinninti, Swetha, Berthaud, Vladimir, Gupta, Anil, Creech, C Buddy, Dietrich, Monika, Xu, Wenqin, Das, Rituparna, Slobod, Karen, Kelly, Roxanne, Zhao, Xiaoping, Carr, Quito, Anderson, Evan J, Javita, David, Deng, Weiping, Brown, Mollie, Zhou, Honghong, Luzuriaga, Katherine, Schnyder Ghamloush, Sabine, Towner, William   +26 more
core   +2 more sources

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination [PDF]

Vaccines, 2022
The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or
Oleguer Parés-Badell, Ricardo Zules-Oña, Lluís Armadans, Laia Pinós, Blanca Borrás-Bermejo, Susana Otero, José Ángel Rodrigo-Pendás, Martí Vivet-Escalé, Yolima Cossio-Gil, Antònia Agustí, Cristina Aguilera, Magda Campins, Xavier Martínez-Gómez   +12 more
doaj   +2 more sources

Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines [PDF]

Frontiers in Cardiovascular Medicine, 2023
ImportanceThere is a high level of public and professional interest related to potential safety issues of the COVID-19 vaccines; however, no serious adverse cardiovascular events were reported in phase 3 randomized controlled trials of their safety and ...
Manan Pareek, Manan Pareek, Pasquale Sessa, Paolo Polverino, Francesco Sessa, Kristian Hay Kragholm, Maurizio Sessa   +6 more
doaj   +2 more sources

Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies

Vaccines, 2022
Although numerous COVID-19 vaccines are effective against COVID-19 infection and variants of concern (VOC) in the real world, it is imperative to obtain evidence of the corresponding vaccine effectiveness (VE).
Shuailei Chang, Hongbo Liu, Jian Wu, Wenwei Xiao, Sijia Chen, Shaofu Qiu, Guangcai Duan, Hongbin Song, Rongguang Zhang   +8 more
doaj   +2 more sources